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THE PROBLEM
Protein drugs have a tendency to 
aggregate, which adversely affects 
their shelf life and delivery as a 
stable drug formulation. Of the top 
100 drugs by U.S. sales in the fourth 
quarter of 2012, 28 were protein 
drugs or other biologics (source: IMS 
Health, http://www.imshealth.com). 
More than 100 genuine, and similar 
numbers of modified, therapeutic 
proteins are approved for clinical 
use in the European Union and the 
USA, with 2010 sales of 108 billion 
(US$) (Dimitrov, 2012). Thus, there is 
a high demand for protein drugs, but 
any positive consequences of protein 
drugs are inaccessible if these drugs 
cannot be stored and delivered in a 
stable form. Therapeutic effects of 
the protein drugs are dependent on 
the specific primary structure of the 
proteins. During Aggregation, the 
protein irreversibly loses its unique 
shape, and thus its function. The 
aggregation process can occur due to 
physical interactions between protein 
surfaces or can result from chemical 
interactions of the amino acids, 
forming covalent bonds between 
proteins (Wang, 2005).
Lyophilization is the primary 
method used in the industry to 
improve the stability of protein 
drug formulations. Lyophilization 
removes water from the formulation 
by sublimation via a freezing step 
and then by evaporation through 
primary and secondary drying 
steps (Cleland, Langer et al. 1994; 
Costantino and Pikal 2004). The idea 
is to improve stability of the protein 
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by removing water to decrease its 
mobility and make it less vulnerable 
to water-based reactions. Even after 
this process, proteins may lose their 
native structure due to aggregation, 
leaving lyophilization alone as a 
dubious solution.
PROPOSED SOLUTION
The aim of this project is to find an 
effective, cheap and efficient method 
to develop stable formulations 
for protein drugs which are not 
vulnerable to aggregation and 
in turn have stable shelf life and 
effective delivery. A method using 
a combination of computer-aided 
molecular design and molecular 
docking simulations is proposed to 
find a specific optimum formulation 
for a specific protein, minimizing 
aggregation probability. 
The choice of excipient in the 
protein drug formulation can lower 
the probability of protein aggregation 
through interactions between the 
excipient and hot spots on the 
protein. Excipients are inactive 
ingredients in the drug product 
that help hold a dose of the active 
pharmaceutical ingredient (API) 
together and keep it stable for a 
long shelf life (Ritter, 2008). Hot 
spots are aggregation-prone regions 
on a protein. In this project, a pool 
of candidate sugar and surfactant 
excipients is chosen based on specific 
physical and chemical properties. For 
each candidate excipient, molecular 
docking simulation is conducted with 
the protein. The interactions of the 
excipients with the hot spots on the 
protein are fed into Computer Aided 
Molecular Design (CAMD) which 
determines the optimum excipient 
formulation for that specific protein. 
METHOD
The pool of excipient candidates are 
chosen based on their physical and 
chemical properties. An excipient 
having a high glass transition 
temperature is preferred. In the case 
of sugar excipients, glass transition 
temperature refers to phase change. 
Higher glass transition temperature 
means less mobility and more 
stability. Another aspect looked at 
is the water content in a lyophilized 
excipient-protein solid. Lower water 
content is preferred because removal 
of water slows down water-based 
reactions and also reduces protein 
mobility. Furthermore, the lower 
the protein loss after lyophilization, 
the better the excipient-protein 
combination will function. Loss of 
monomeric protein may indicate 
protein aggregation.
 The next step is to model the 
interactions of this pool of excipient 
candidates with the protein. 
Molecular docking simulations of 
each protein-excipient combination 
are done in Autodock. The excipients 
looked at in this work are designed 
to provide stabilizing interactions 
for the protein myoglobin. In order 
to apply molecular docking, two 
commonly used excipients, the 
sugars sucrose and mannitol, have 
been investigated so far. Some of the 
surfactants which will be looked at 
as excipients in the future include 
Octyl glucoside, Tween 40 and Tween 
80. Molecular docking simulations 
performed using Autodock predicted 
which residues were most likely 
to interact with the excipient in 
question. AutoDock employs a 
grid-based approach along with a 
semi-empirical free energy force 
field to identify interaction sites with 
minimal free energy. 
 Each simulation in Autodock 
provided ten docking conformations, 
which represent a local minimum free 
energy state. Ten docking simulations 
were performed for each excipient 
with myoglobin, providing a hundred 
docking conformations total for each 
excipient. Each conformation was 
evaluated to determine residues which 
were repeatedly involved in strong 
interactions (Van der Waal or hydrogen 
bonding) with the excipients.
The computational results from 
the above procedure were compared 
to experimental hydrogen-deuterium 
exchange (HDX) mass spectrometry 
experiments using lyophilized 
formulations of myoglobin 
with either sucrose or mannitol 
(Sophocleous, et al., 2012). The 
regions on the protein which exhibit 
free exchange between hydrogen 
and deuterium are uncovered 
and not protected by the protein-
excipient interactions. Therefore, 
protein regions which show low 
deuterium uptake are protected by 
the excipient interactions covering 
those regions. These regions of 
low deuterium uptake are then 
correlated with protein-excipient 
interactions predicted by molecular 
docking simulations, to validate the 
simulation results. 
Figure 1 below shows the concept 
by illustrating a ‘perfect match’:
RESULTS
Results were obtained from the 
execution of molecular docking 
simulations, providing 100 
conformations for both myoglobin-
mannitol and myoglobin-sucrose. 
The results were analyzed and 
compared with the results of HDX 
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two pairs in the lyophilized state.  
Figure 2 shows the results for the 
HDX exchange experiments for those 
two excipient-protein pairs. Figure 
2 is a histogram which presents the 
strength of molecular interactions 
at various residue locations, for 
both the simulation results and the 
HDX experimental results. Overall, 
the docking results compared 
favorably with the HDX results. 
Regions of high interaction in the 
docking simulations corresponded 
to regions that were protected from 
hydrogen-deuterium exchange. The 
regions which were protected by 
the excipients in the lyophilized 
state showed low deuterium uptake. 
These regions correspond to residue-
excipient pairs, with sucrose and 
mannitol showing high frequency 
of interactions. Thus, the simulation 
predictions demonstrate utility as 
a formulation selection tool. The 
HDX experimental results show 
that the sucrose-myoglobin system 
always shows a lower deuterium 
uptake then the mannitol-myoglobin 
combination. For the simulations, the 
excipient (sucrose or mannitol) with 
higher interaction with a specific 
amino acid can be selected. An 
approximation made by the Autodock 
simulation algorithm is that the 
protein molecule remains rigid. While 
this simplification certainly suggests 
that the results of simulations alone 
should not guide formulation design, 
the use of Autodock in combination 
with the other software tools for 
screening of excipient candidates is 
not hampered.
Data provided by the docking 
simulations is used to optimally 
select excipients that have the 
highest number of interactions with 
aggregation-prone “hot spots.” The 
hot spots were predicted using 
Aggrescan (Conchillo-Sole et al., 
2007). For each hot spot, a sugar and 
a surfactant molecule are chosen 
to maximize protein-excipient 
interactions. For selection purposes, 
whichever excipient has the most 
interactions with a particular residue 
is chosen as the best candidate. It 
is assumed that the molecule with 
the most interactions with a residue 
would have the dominant effect 
and thus contribute the most to the 
protection of the residue of interest. 
The method may also be used to 
compare classes of excipients. For 
example, at each residue in the hot 
spot, the best sugar candidate and 
the best surfactant candidate can 
be compared. Whichever excipient 
had the most interactions is then 
selected and the process is repeated 
for the entire hot spot sequence. The 
sugar-surfactant pair providing the 
maximum number of interactions 
is selected as the optimal drug 
formulation. This part of the method 
aims to utilize Computer Aided 
Molecular Design (CAMD). Figure 3 
summarizes the whole methodology: 
A pool of excipient candidates, 
including surfactants and sugars, is 
selected based on certain physical 
and chemical properties.
Molecular docking simulations 
Fig. 2: Frequency of amino acid residues of Myoglobin in contact with sucrose 
and mannitol. Results are given for 100 docking conformations. The completely 
shaded regions in green indicate the amino acids that were protected by the 
excipient in the lyophilized state, as determined by HDX experiments.
Fig. 3
A pool of excipient 
candidates, including 
surfactants and sugars, is 
selected  based on certain 
physical and chemical 
properties.
Molecular docking 
simulations are used to 
model excipient 
interactions with the hot 
spot regions on the 
protein.
 Optimization is used 
to select an excipient 
combination which 
provides the most 
interactions with the 
residues in the hot 
spot region.
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are used to model excipient 
interactions with the hot spot 
regions on the protein.
Optimization is used to select 
an excipient combination which 
provides the most interactions with 
the residues in the hot spot region.
CONCLUSIONS AND 
FUTURE WORK
The hydrogen-deuterium exchange 
experiments were performed 
specifically to establish the utility 
of molecular docking simulations 
for the determination of the best 
excipients for a protein. For example, 
25 excipient candidates may be 
generated for a particular protein 
using computer aided molecular 
design, based upon three properties 
of interest: high glass transition 
temperatures, low water content in 
the lyophilized state and minimum 
protein mass loss on lyophilization. 
The molecular docking simulation 
method can then be used to quickly 
screen this group into a short, ranked 
list of excipients for that protein. 
Formulations of different excipients 
which give optimal interactions 
with the hotspot regions of the 
proteins can also be determined. This 
procedure significantly decreases 
the time and resources expended 
in the search for novel excipients. 
Thus, this work aids in the ability 
to predict the optimal excipient for 
any provided protein, allowing the 
pharmaceutical industry to better 
develop safe, effective and financially 
viable protein drugs.
An approximation made by the 
Autodock simulation algorithm is 
that the protein molecule remains 
rigid. Molecular docking simulations 
will be run in AutoDock Vina to see 
if that minimizes this approximation. 
Furthermore, additional proteins and 
excipients will be added in the dataset 
to obtain a more detailed and flexible 
tool for protein formulation design. 
ACKNOWLEDGMENTS
Professor Kyle V. Camarda, Chemical 
and Petroleum Engineering, 
University of Kansas
Brock C. Roughton, Phd Chemical 
Engineering, University of Kansas, 
2013.
Molecular Graphics and Modeling 
Lab, Molecular Structures Group,
University of Kansas.
APPENDIX
The structure of the protein was 
obtained in the PDB file format 
from the Protein Data Bank (http://
www.rcsb.org/pdb/home/home.
do). Structural information about 
the excipients was accessed via files 
in 3D-SDF format obtained from 
PubChem online (http://pubchem.
ncbi.nlm.nih.gov/). Because Autodock 
cannot read sdf files, excipient files 
were converted to 3D-mol format 
using the CACTUS online toolkit 
(http://cactus.nci.nih.gov/translate/).
Docking Using ADT (Pokphanh, 2011).
Fig. 4: A docking conformation of Octyl Glucoside with 
Myoglobin in Autodock.
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